US 11,897,960 B2
Anti-IL-4R antibody and use thereof
Zhigang Liu, Beijing (CN); Yulan Liu, Beijing (CN); Xiaobo Hao, Beijing (CN); Lei Jiang, Beijing (CN); and Jingjing Guo, Beijing (CN)
Assigned to Beijing Wisdomab Biotechnology Co., Ltd, Beijing (CN); Genrix (Shanghai) Biopharmaceutical Co. Ltd., Shanghai (CN); and Chongqing Genrix Biopharmaceutical Co., Ltd., Chongqing (CN)
Appl. No. 17/049,288
Filed by Beijing Wisdomab Biotechnology Co., Ltd, Beijing (CN); Genrix (Shanghai) Biopharmaceutical Co. Ltd., Shanghai (CN); and Chongqing Genrix Biopharmaceutical Co., Ltd., Chongqing (CN)
PCT Filed Aug. 13, 2018, PCT No. PCT/CN2018/100263
§ 371(c)(1), (2) Date Oct. 20, 2020,
PCT Pub. No. WO2019/200787, PCT Pub. Date Oct. 24, 2019.
Claims priority of application No. 201810360234.5 (CN), filed on Apr. 20, 2018.
Prior Publication US 2022/0081485 A1, Mar. 17, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/565 (2013.01)] 18 Claims
OG exemplary drawing
 
1. An antibody that binds to human IL-4R comprising a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 and a light chain variable region comprising LCDR1, LCDR2 and LCDR, wherein
the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO: 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO: 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO: 35), the LCDR1 has the sequence of RSSQSLLYSIGYNYLD (SEQ ID NO: 36), the LCDR2 has the sequence of LGSNRAS (SEQ ID NO: 37), and the LCDR3 has the sequence of MQSFKAPYT (SEQ ID NO: 38); or
the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO: 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO: 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO: 35), the LCDR1 has the sequence of RSSRNVIYGNGYNYLD (SEQ ID NO: 39), the LCDR2 has the sequence of LGNNVAA (SEQ ID NO: 40), and the LCDR3 has the sequence of MQSLQAPYT (SEQ ID NO: 41); or
the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO: 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO: 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO: 35), the LCDR1 has the sequence of RSSQNVYGNGYNYLD (SEQ ID NO: 42), the LCDR2 has the sequence of LGTNVAA (SEQ ID NO: 43), and the LCDR3 has the sequence of MQSLQAPYT (SEQ ID NO: 41); or
the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO: 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO: 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO: 35), the LCDR1 has the sequence of RSSQNVYGNGYNYLD (SEQ ID NO: 42), the LCDR2 has the sequence of LGNNVAA (SEQ ID NO: 40), and the LCDR3 has the sequence of MQSLKAPYT (SEQ ID NO: 44); or
the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO: 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO: 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO: 35), the LCDR1 has the sequence of RSSHNLLYSNGYNYLD (SEQ ID NO: 45), the LCDR2 has the sequence of LGSNRAY (SEQ ID NO: 46), and the LCDR3 has the sequence of MQALQSPYT (SEQ ID NO: 47);
the HCDR1 has the sequence of GFTFSSYAMS (SEQ ID NO: 33), the HCDR2 has the sequence of SITGGGGGIYYADSVKG (SEQ ID NO: 34), the HCDR3 has the sequence of DRISITIRPRYFGLDF (SEQ ID NO: 35), the LCDR1 has the sequence of RSSQSLLYSNGYNYLD (SEQ ID NO: 48), the LCDR2 has the sequence of LGSNRAS (SEQ ID NO: 37), and the LCDR3 has the sequence of MQALETPYA (SEQ ID NO: 49);
wherein the HCDR and LCDR are defined according to Kabat.